Dr. Ram Yogendra
speaker
332 appearances
3 recordings
1 series
first heard May 2025
last heard 13 Aug
Dr. Ram Yogendra’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsRecordings per month over the last 12 months — 2 in all, peaking in Aug 2026 with 2.
Appearances
in how these journals are reviewing articles and papers. For example, it can't just come from some of the elite institutions, because there are some great researchers, as you know, over the years and interviewing other researchers who are not in these big academic centers, they're private investigators.
Absolutely. And like I said, it's a it's a medical oligarchy. Right. So we would get interviewed by by mainstream media, which, by the way, I you know, I get Washington Post and New York Times reporters trying to contact me about our research. And I just kind of give them the Elon respond GFY because, you know, what they'll do is they will they will go.
They will go and they will interview Bruce and I, get a little quote, and then they'll go to the expert who will then try to discredit us.
And it turns out most of the experts and these people that crapped on us all had conflicts of interest, whether they were paid by pharma, which if you go to openpayments.gov, you can look and see who's been paid by pharma, or they have some sort of competing interests between a lab or some research that they're trying to do.
Yeah, so we've actually got, so we're doing a, the FDA has approved a clinical trial with long COVID, which is studying the spike proteins and the vascular monocytes from the COVID infection. We actually have congressional support.
Well, we're going to do both. So right now, what we're working on is Senator Todd Young has really been a big supporter of us, and he's helping us with Congressman Pete Stauber in Minnesota and Congressman Jeff Crank in Colorado.
who are just running up and down the halls of uh in dc uh trying to help us right now which is uh which is incredible and i know a lot of people saw uh senator young uh with the rfk confirmation and he's been really a big uh advocate for the the long covet community and which was a testament because one of the things i want to mention is that you know this whole there's a whole division an argument about long covet and long backs and it's
Sort of a right wing versus left. And we've got a lot of support from from the GOP side. And I keep telling people this long COVID is not a left wing liberal disease. You know, this is this is something. You're right, this is something actually GOP, we've got more congressional Republican senators and congressmen behind us than unfortunately our Democrat side and shouldn't be political.
So we got an FDA approved clinical study that we're trying to get funding to and hopefully we should have, we've got a couple of leads that Senator Young is working on. Now that this paper- This is for treatment?
Yeah, it's a morale bracket. Marabara, ketorvastatin, phase three FDA approved clinical trial that in 16 weeks if the trial is successful, we'll have the first approved medication for long COVID. And what I've done, I've actually just finished writing the protocol now that our vaccine paper is published, is a phase three clinical trial for post COVID vaccine syndrome.
which we're submitting to the FDA in about a week, and then hopefully get funding to run. Is that a different protocol? It's a different protocol. Yep, that's a different protocol we're going to submit to the FDA.
Yeah, again, it's the same thing. It's a Mirovac and a statin combination, but the patient population is going to be different. We're going to look at vaccine-injured patients and then screen them one year not having a COVID infection. You know, here's the thing, Drew, that's difficult about studying the vaccine group right now because many of them got COVID afterwards, so it sort of muddies up.
That the argument could be made as well, is this because of COVID or is this because of the vaccine?
That's what we're doing. So what we're doing is we're saying if you had a vaccine injury, a documented vaccine injury, regardless of the time period, and you haven't had a COVID infection in the past year, you're enrolled in the study. When the paper comes out, you'll see there are different immune markers with the vaccine group compared to the COVID group.
But right now, if you're trying to study this, it's going to be a mix because people that had vaccine injuries got COVID, and it's a big mishmash of things right now.
yeah so that's so that's the next thing you know i think the focus should be you know there's a lot of anything rightfully so discussions on the code uh the vaccines and the mandates and all of that that's going on but i think a lot of discussion needs to be made but we need to have more discussion with running clinical trials and get therapeutics you know i've been reading some some articles and and speculation that
We're looking at about maybe 15 to 20 vaccine-injured patients in the United States, along with another 20 million or more that have long COVID. So if you take those numbers, you're looking at about 40 million, 50 million Americans that have COVID. long COVID or backs injured, you know, we're looking at about 15, 20% of the American population.
So, you know, and, and, you know, instead of looking maybe back and trying to point fingers, I, I'm more focused on looking forward and saying, how can we helping people helping, right?
Yeah, you know what's really interesting? Some of these long COVID patients and even the vaccine-injured patients, what we're doing is we're actually finding also Lyme in them too. So we're finding reactivated herpes infections. The Yale study found that some of these vaccine-injured patients had low CD4 counts. There's some sort of immunosuppression taking place.
And with our long COVID patients, we saw CD8 counts that are low.
Showing 301–320 of 332 · page 16 of 17
← Previous
Next →